Mesenchymal Stem Cell Membrane‐Camouflaged Liposomes for Biomimetic Delivery of Cyclosporine A for Hepatic Ischemia‐Reperfusion Injury Prevention

• Published in: Advanced science Vol. 11; no. 32; pp. e2404171 - n/a
• Main Authors: Chen, Haitian, Yin, Wen, Yao, Kang, Liang, Jinliang, Cai, Jianye, Sui, Xin, Zhao, Xuegang, Zhang, Jiebin, Xiao, Jiaqi, Li, Rong, Liu, Qiuli, Yao, Jia, You, Guohua, Liu, Yasong, Jiang, Chenhao, Qiu, Xiaotong, Wang, Tingting, You, Qiang, Zhang, Yingcai, Yang, Mo, Zheng, Jun, Dai, Zong, Yang, Yang
• Format: Journal Article
• Language: English
• Published: Germany John Wiley & Sons, Inc 01.08.2024; John Wiley and Sons Inc; Wiley
• Subjects: Animals; Apoptosis; biomimetic delivery; Biomimetics - methods; Cyclosporine - administration & dosage; Cyclosporine - pharmacology; cyclosporine A; Disease Models, Animal; Drug Delivery Systems - methods; Drug dosages; Health care; Homeostasis; Ischemia; ischemia‐reperfusion injury; Liposomes; Liver; Liver - drug effects; Liver - metabolism; Male; Membranes; mesenchymal stem cell; Mesenchymal Stem Cells - drug effects; Mesenchymal Stem Cells - metabolism; Mice; Mice, Inbred C57BL; Mitochondria; Particle size; Prevention; Proteins; Reperfusion Injury - prevention & control; ischemia‐reperfusion injury; mesenchymal stem cell; cyclosporine A; biomimetic delivery

Hepatic ischemia‐reperfusion injury (HIRI) is a prevalent issue during liver resection and transplantation, with currently no cure or FDA‐approved therapy. A promising drug, Cyclosporin A (CsA), ameliorates HIRI by maintaining mitochondrial homeostasis but has systemic side effects due to its low bi...